Sugi Predict

Sugi Predict / Compounds / SCHEMBL219867

SCHEMBL219867

SCHEMBL219867

[CH2]Cc1cc2ccccc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.64
▸ AHR P35869 2/20 0.50
▸ HRH3 Q9Y5N1 1/20 0.50
▸ HRH4 Q9H3N8 1/20 0.49
▸ AOC3 Q16853 2/20 0.48
▸ MTNR1A P48039 1/20 0.47
▸ MTNR1B P49286 1/20 0.47
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ IDO1 P14902 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL153397 0.83 LOXL2 (0.60) LOXL2AHRHRH3HRH4AOC3
SCHEMBL3115121 0.83 LOXL2 (0.64) LOXL2AHRHRH3HRH4AOC3
SCHEMBL28338445 0.82 LOXL2 (0.69) LOXL2AHRHRH3HRH4AOC3
SCHEMBL31059889 0.82 LOXL2 (0.69) LOXL2AHRHRH3HRH4AOC3
SCHEMBL7169246 0.82 LOXL2 (0.69) LOXL2AHRHRH3HRH4AOC3
SCHEMBL401081 0.82 LOXL2 (0.69) LOXL2AHRHRH3HRH4AOC3
SCHEMBL29403791 0.82 LOXL2 (0.69) LOXL2AHRHRH3HRH4AOC3
SCHEMBL5460356 0.80 LOXL2 (0.56) LOXL2AHRHRH3HRH4MTNR1A
SCHEMBL28335219 0.80 LOXL2 (0.67) LOXL2AHRHRH3AOC3MTNR1A
SCHEMBL1229637 0.79 LOXL2 (0.60) LOXL2AHRHRH3MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1055 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240189360-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS 7 HILLS PHARMA INC. (US) 2024-06-13 — — US claimed
WO-2023217764-A1 NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2023-11-16 — — WO claimed
US-11311619-B2 Integrin activator vaccine compositions 7 Hills Pharma Inc. and Texas Heart Institute (US) 2022-04-26 — — US claimed
US-20220001009-A1 NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND 7 Hills Pharma LLC (US) 2022-01-06 — — US claimed
EP-3894396-A1 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS Ideaya Biosciences, Inc. (US) 2021-10-20 — — EP claimed
CN-113166078-A 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors 伊迪亚生物科学有限公司 2021-07-23 — — CN claimed
US-20210177811-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER CALLIDITAS THERAPEUTICS SUISSE SA (CH) 2021-06-17 — — US claimed
US-20210145796-A1 METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY 7 HILLS PHARMA INC. 2021-05-20 — — US claimed
US-20210023207-A1 NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS 7 Hills Pharma LLC (US) 2021-01-28 — — US claimed
EP-3703747-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER GenKyoTex Suisse SA (CH) 2020-09-09 — — EP claimed
EP-0254032-A2 Neutral metalloendopeptidase inhibitors in the treatment of hypertension SCHERING CORPORATION (US) 1988-01-27 — — EP claimed
EP-0227818-A1 ANTIGLAUCOMA COMPOSITIONS. SCHERING CORP (US) 1987-07-08 — — EP claimed
WO-1987000055-A1 ANTIGLAUCOMA COMPOSITIONS SCHERING CORPORATION (US) 1987-01-15 — — WO claimed
EP-0061186-B1 DIPEPTIDES CONTAINING THIALYSINE AND HOMOLOGS AS ANTIHYPERTENSIVES MERCK & CO. INC. (US) 1986-05-21 — — EP claimed
EP-0061768-B1 N-AMIDO SUBSTITUTED DIPEPTIDES USV PHARMACEUTICAL CORPORATION (US) 1986-05-14 — — EP claimed
US-4512979-A Dipeptides containing thialysine and related amino acids as antihypertensives MERCK & CO., INC. (US) 1985-04-23 — — US claimed
EP-0132964-A2 2-Azabicyclo[2.2.2]octane derivatives RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 1985-02-13 — — EP claimed
US-4496542-A HYPOTENSIVE AGENTS; ENZYME INHIBITORS USV PHARMACEUTICAL CORPORATION (US) 1985-01-29 — — US claimed
EP-0061768-A1 N-amido substituted dipeptides USV PHARMACEUTICAL CORPORATION (US) 1982-10-06 — — EP claimed
EP-0061186-A1 Dipeptides containing thialysine and homologs as antihypertensives MERCK & CO. INC. (US) 1982-09-29 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11311619-B2 Integrin activator vaccine compositions ITGAM, ITGA2B, ITGA1 LOXL2 2359/4885AHR 3341/4885HRH3 2178/4885
US-20220001009-A1 NOVEL COMPOSITIONS INCLUDING A THERAPEUTIC ANTIBODIES AND/OR A CHECKPOINT INHIBITOR AND AN INTEGRIN ACTIVATING COMPOUND CD47, ITGB1, ITGAM LOXL2 1649/4885AHR 3712/4885HRH3 1178/4885
US-20210145796-A1 METHODS FOR ADMINISTERING COMPOSITIONS INCLUDING INTEGRIN AGONISTS HAVING ANTI-TUMOR ACTIVITY ITGB7, ITGA1, ITGAL LOXL2 389/4885AHR 2869/4885HRH3 1394/4885
US-20210023207-A1 NOVEL INTEGRIN ACTIVATOR VACCINE COMPOSITIONS ITGA2B, ITGAM, ITGAV LOXL2 2496/4885AHR 3606/4885HRH3 1952/4885
US-20240189360-A1 COMPOSITIONS AND METHODS TO IMPROVE THE HOMING AND GRAFTING OF HEMATOPOETIC STEM CELLS CXCL12, ITGB3, ITGB7 LOXL2 1370/4885AHR 1096/4885HRH3 994/4885
US-20210177811-A1 USE OF NOX INHIBITORS FOR TREATMENT OF CANCER NOX1, NOX5, NOX3 LOXL2 845/4885AHR 2295/4885HRH3 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.